The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell ...

New results from a pooled analysis of patients with previously treated EGFR-mutated NSCLC in the TROPION-Lung05 and TROPION-Lung01 trials will be featured in a late-breaking presentation at the ...

The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona. Amongst the excited hustle and bustle of new data and ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient ...

Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for ...

Medscape Medical News, October 10 ... and newer cancer therapies on fertility at the recent congress of the European Society for Medical Oncology.

Net financial result for the three and nine months ended September 30, 2024, amounted to €2.2 million and €8.0 million, or a decrease of €3.1 million and €4.7 million, from €5.3 million and €12.7 ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Investigators report findings from a phase 3 trial demonstrating that transdermal estradiol patches were as effective as luteinizing hormone-releasing hormone agonists.

Panelist discusses how an early analysis of the mechanisms of acquired resistance to first-line treatment with amivantamab ...

EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...